Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Leukemia, Myeloid, Acute 35Neoplasm Metastasis 32Myelodysplastic Syndromes 18Lung Neoplasms 16Colorectal Neoplasms 14Pancreatic Neoplasms 12Breast Neoplasms 12Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Melanoma 9Glioblastoma 9Lymphoma, Follicular 8Carcinoma, Renal Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 7Astrocytoma 7Ovarian Neoplasms 6Glioma 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, T-Cell 5Lymphoma, Mantle-Cell 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Stomach Neoplasms 4

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Specimen Handling × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03107780 2025-11-13

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
32 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡